

TSH Biopharm launches Guzip's Mpap Test, a new endometrial cancer screening test, from May in Taiwan

2020/04/30

TSH Biopharm announced today (4/30) that TSH Biopharm launches Guzip's Mpap Test, a new endo-metrial cancer screening test, from May in Taiwan.



Endometrial cancer arises from the endometrium. It is the result of the abnormal growth of cells that can invade or spread to other parts of the body. There are many high-risk groups for the endometrial cancers including female over 40 years old; obesity; early menstruation and later menopause; never gave birth; breast cancer patients under Tamoxifen treatment.

The most updated data indicates the incident rate of Endometrial cancer is 20.83/100,000 female, and 2,462 new cases in 2016 from Taiwan.

The most common symptom of endometrial cancer is abnormal uterine bleeding, especially bleeding after menopause, and other symptoms include dysuria (painful urination) or pelvic pain. But there is no specific test available for endometrial cancer considering all the symptoms are shared with multiple kind of gynecology diseases.

MPap is a Taiwan and worldwide patent protected innovative diagnosis, which employ Methylation-Specific PCR technology to test specific genes methylation status from the smear sample, and medical doctors can identify the high risk subjects through this tests and reduce non-necessary invasive diagnosis operations.

Before MPap, there is no gene testing focus on endometrial cancers on the diagnostic market. Physicians use vaginal ultrasound for the first screening and endometrial scraping/ hysteroscope for the diagnosis. Through MPap launched, Gynaecologists can have convenient with high sensitivity/ specificity tool for endometrial cancer screen.